Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MCLA-117 in adult acute myeloid leukemia and high-risk myelodysplastic syndrome
NL-OMON47785Phase 1Active, not recruiting
- Sponsor
- Merus
- Start
- Apr 2016
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tepoditamab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Merus. Primary endpoints: Safety and tolerability and Preliminary clinical efficacy. Started Apr 2016; status: active, not recruiting.
02
Drugs
tepoditamab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON47785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47785.